Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SAVA Stock Forecast 2025-2026
$2.05
Current Price
$108.21M
Market Cap
Buy 0
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to SAVA Price Targets
-2.4%
To High Target of $2.00
-2.4%
To Median Target of $2.00
-2.4%
To Low Target of $2.00
SAVA Price Momentum
0.0%
1 Week Change
+28.9%
1 Month Change
-90.7%
1 Year Change
-13.1%
Year-to-Date Change
-95.1%
From 52W High of $42.20
+78.3%
From 52W Low of $1.15
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Cassava (SAVA) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on SAVA and similar high-potential opportunities.
Latest SAVA Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, SAVA has a neutral consensus with a median price target of $2.00 (ranging from $2.00 to $2.00). Currently trading at $2.05, the median forecast implies a -2.4% downside. This outlook is supported by 0 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Vernon Bernardino at HC Wainwright & Co., projecting a 2.4% downside. Conversely, the most conservative target is provided by Vernon Bernardino at HC Wainwright & Co., suggesting a 2.4% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SAVA Analyst Ratings
0
Buy
2
Hold
0
Sell
SAVA Price Target Range
Low
$2.00
Average
$2.00
High
$2.00
Current: $2.05
Latest SAVA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SAVA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 25, 2025 | HC Wainwright & Co. | Vernon Bernardino | Neutral | Reiterates | $2.00 |
| Mar 4, 2025 | HC Wainwright & Co. | Vernon Bernardino | Neutral | Reiterates | $0.00 |
| Nov 26, 2024 | HC Wainwright & Co. | Vernon Bernardino | Neutral | Downgrade | $116.00 |
| Nov 8, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $116.00 |
| Oct 8, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Upgrade | $116.00 |
| Aug 13, 2024 | HC Wainwright & Co. | Vernon Bernardino | Neutral | Reiterates | $0.00 |
| Aug 8, 2024 | Rodman & Renshaw | Elemer Piros | Buy | Reiterates | $107.00 |
| Jul 19, 2024 | HC Wainwright & Co. | Vernon Bernardino | Neutral | Reiterates | $0.00 |
| Jul 1, 2024 | Jones Trading | Soumit Roy | Hold | Downgrade | $0.00 |
| Jul 1, 2024 | HC Wainwright & Co. | Vernon Bernardino | Neutral | Downgrade | $0.00 |
| May 17, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Maintains | $131.00 |
| Mar 5, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $124.00 |
| Aug 8, 2023 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $124.00 |
| Jul 6, 2023 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $124.00 |
| May 11, 2023 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $124.00 |
| May 9, 2023 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $124.00 |
| Mar 6, 2023 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $124.00 |
| Jan 24, 2023 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $124.00 |
| Aug 11, 2022 | B. Riley Securities | Mayank Mamtani | Buy | Maintains | $44.00 |
| Jan 24, 2022 | B. Riley Securities | Mayank Mamtani | Buy | Maintains | $72.00 |
Cassava Sciences Inc. (SAVA) Competitors
The following stocks are similar to Cassava based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
SAVA
Cassava Sciences
mkt cap
99.03M
Cassava Sciences Inc. (SAVA) Financial Data
Cassava Sciences Inc. has a market capitalization of $108.21M with a P/E ratio of -3.9x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -70.6%.
Valuation Metrics
Market Cap
$108.21M
Enterprise Value
$-17,330,656
P/E Ratio
-3.9x
PEG Ratio
-1.3x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+118.5%
Current Ratio
9.1x
Debt/Equity
0.0x
ROE
-70.6%
ROA
-59.0%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Cassava Sciences Inc. (SAVA) Business Model
About Cassava Sciences Inc.
What They Do
Develops treatments for neurodegenerative diseases.
Business Model
The company focuses on addressing unmet medical needs in Alzheimer's treatment through its lead product candidate, simufilam, which aims to enhance cognitive and behavioral functions. Additionally, it is developing SavaDx, a diagnostic tool for Alzheimer's detection via blood tests, thereby diversifying its revenue potential.
Additional Information
Headquartered in Austin, Texas, Cassava Sciences is positioned in the competitive biotech landscape, leveraging innovative research to potentially revolutionize the healthcare and pharmaceutical industries. The company's advancements could lead to significant breakthroughs in both diagnostics and therapeutics for neurodegenerative diseases.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
30
CEO
Mr. Richard Jon Barry
Country
United States
IPO Year
2000
Website
www.cassavasciences.comCassava Sciences Inc. (SAVA) Latest News & Analysis
Latest News
Quick Summary
Cassava Sciences, Inc. has appointed Dr. Angélique Bordey as Senior Vice President of Neuroscience to lead R&D, focusing on simufilam for TSC-related epilepsy and other indications.
Why It Matters
Dr. Bordey's appointment signals a strengthened leadership in R&D at Cassava, potentially enhancing the development of simufilam and other CNS treatments, impacting future stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cassava Sciences announced the retirement of Chief Medical Officer James W. Kupiec, effective May 9, 2025, and appointed Jack Moore, PhD, as Senior VP of Clinical Development.
Why It Matters
Leadership changes can impact a company's strategic direction and investor confidence. The retirement of a CMO may signal shifts in clinical focus or uncertainty in ongoing trials, affecting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cassava Sciences (SAVA) is currently in oversold territory, and analysts are raising earnings estimates, suggesting a potential trend reversal for the stock.
Why It Matters
Cassava Sciences (SAVA) may be poised for a rebound, as oversold conditions and positive analyst revisions suggest potential upward momentum, attracting investor interest.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Cassava Sciences faces uncertainty in growth prospects following the failure of a late-stage study on its Alzheimer's disease candidate.
Why It Matters
Cassava Sciences' failed Alzheimer's trial raises concerns over its growth potential and future revenue, likely leading to decreased investor confidence and stock volatility.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Cassava Sciences' lawsuit to dismiss a malicious prosecution claim by doctors and short-sellers regarding its Alzheimer's drug simufilam was unsuccessful, as the drug is set to be discontinued.
Why It Matters
Cassava's legal troubles could undermine investor confidence, impacting stock performance and raising concerns about the viability of its Alzheimer's drug, simufilam.
Source: Reuters
Market Sentiment:
Negative
Quick Summary
Cassava stock fell 32% after its Alzheimer's drug did not meet key endpoints in a second late-stage trial.
Why It Matters
Cassava's stock plunge reflects investor concern over the failed Alzheimer's drug, signaling potential revenue loss and heightened uncertainty about the company's future prospects.
Source: Zacks Investment Research
Market Sentiment:
Negative
Frequently Asked Questions About SAVA Stock
What is Cassava Sciences Inc.'s (SAVA) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, Cassava Sciences Inc. (SAVA) has a median price target of $2.00. The highest price target is $2.00 and the lowest is $2.00.
Is SAVA stock a good investment in 2025?
According to current analyst ratings, SAVA has 0 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.05. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SAVA stock?
Wall Street analysts predict SAVA stock could reach $2.00 in the next 12 months. This represents a -2.4% decrease from the current price of $2.05. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cassava Sciences Inc.'s business model?
The company focuses on addressing unmet medical needs in Alzheimer's treatment through its lead product candidate, simufilam, which aims to enhance cognitive and behavioral functions. Additionally, it is developing SavaDx, a diagnostic tool for Alzheimer's detection via blood tests, thereby diversifying its revenue potential.
What is the highest forecasted price for SAVA Cassava Sciences Inc.?
The highest price target for SAVA is $2.00 from Vernon Bernardino at HC Wainwright & Co., which represents a -2.4% decrease from the current price of $2.05.
What is the lowest forecasted price for SAVA Cassava Sciences Inc.?
The lowest price target for SAVA is $2.00 from Vernon Bernardino at HC Wainwright & Co., which represents a -2.4% decrease from the current price of $2.05.
What is the overall SAVA consensus from analysts for Cassava Sciences Inc.?
The overall analyst consensus for SAVA is neutral. Out of 6 Wall Street analysts, 0 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $2.00.
How accurate are SAVA stock price projections?
Stock price projections, including those for Cassava Sciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 22, 2025 4:22 AM UTC